10:51 AM EDT, 03/12/2024 (MT Newswires) -- Genprex ( GNPX ) said Tuesday that South Korea's Patent Office has issued it a patent covering the use of its Reqorsa Immunogene Therapy lead drug candidate in combination with anti-PD-1 and PD-L1 antibodies through 2037 to treat cancers.

The patent is applicable to the company's Acclaim-2 and Acclaim-3 trials, Genprex ( GNPX ) said.

Genprex ( GNPX ) shares were down 5% in recent trading.

Price: 4.52, Change: -0.18, Percent Change: -4.98